Actualités

A $2 million investment portfolio can generate a six-figure income stream without tenants, maintenance calls, property tax surprises, or vacancy risk. The arithmetic is straightforward. The challenge is deciding how much yield to pursue and understanding the trade-offs that come with it. To make a fair comparison, start with rental real estate. Many landlords aim ... This $2 Million Portfolio Pays a Six-Figure Income Without Owning a Single Rental Property

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

The Dividend Kings include more than 50 stocks with steadily rising payouts. They’re hard to beat for dividend safety.

With a net profit margin of 21.83%, Johnson & Johnson (NYSE:JNJ) is included among the 12 Most Profitable American Stocks to Buy in 2026. Johnson & Johnson (NYSE:JNJ) and its subsidiaries develop, manufacture, and sell a broad range of healthcare products, giving the company a presence across multiple areas of the healthcare industry. The company’s dividend […]

Johnson & Johnson (NYSE:JNJ) reported Phase 3 results for TALVEY plus DARZALEX FASPRO in relapsed or refractory multiple myeloma, showing improved outcomes versus standard regimens. The MonumenTAL-3 study is the first to show a GPRC5D bispecific antibody combination achieving these results in earlier treatment lines. Findings were published in The New England Journal of Medicine and presented at a major scientific meeting, highlighting clinical and commercial relevance. Johnson & Johnson...

US stocks (^DJI, ^IXIC, ^GSPC) ended Wednesday's session in negative territory after Federal Reserve officials unanimously voted to hold interest rates at their June FOMC meeting today, while also forecasting at least one possible rate hike ahead. Yahoo Finance Markets and Data Editor Jared Blikre breaks down the trading day's market reactions to the Fed's big decision. This was Kevin Warsh's first FOMC meeting he presided over as the new chairman of the Fed.

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.

Johnson & Johnson is focusing on oncology and neuroscience instead of obesity drugs, with AI possibly supporting its next growth cycle.

Kenvue offers both a great short-term and long-term payoff to investors.

Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.

The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.

Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.

Investing.com -- Johnson & Johnson will not enter the obesity drug market, Chief Executive Officer Joaquin Duato said Tuesday. The company plans to concentrate on cancer and neuroscience instead.

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The average retired worker receives roughly $2,000 a month from Social Security. For many retirees, that covers only part of the budget. Building a second Social Security-sized check from dividends can help cover housing, healthcare, travel, family support, or simply provide a larger margin of safety in retirement. The challenge is not finding the right stock. ... How to Build $3,000 a Month in Dividend Income to Cover the Average Social Security Check

Johnson & Johnson (JNJ) spent 2025 proving it could lose a multibillion-dollar drug and still grow. Now it wants to show it can keep doing that for years. On June 13, the company reported results from a late-stage trial of its blood-cancer drug TALVEY, and the data landed at one of the year's ...

Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.

The scenario looks like this: a 63-year-old has built up $850,000 over a working lifetime, watched 2022 and a few scary headlines since, and parked almost all of it in CDs, money market funds, and short Treasuries paying roughly 4%. That throws off about $34,000 a year in interest. It feels prudent. It is also ... Playing It Safe at 63 With $850,000 in Cash and Bonds Is Quietly Costing This Retiree About $34,000 a Year

Joaquin Duato made the comments at a CEO summit in London, where he also said AI is already helping J&J develop medicines faster

Monika Saxena joins the casual-dining chain after eight years as EVP of brand marketing at LongHorn Steakhouse.

AZN shares fell after a camizestrant setback, but blockbuster drugs, oncology growth and a deep pipeline support long-term targets.

Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.

The investment will add J&J’s manufacturing, packaging and distribution capabilities to meet growing demand for its contact lenses.

Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.

Wondering if Johnson & Johnson at around US$235.66 is still a solid deal or starting to look fully priced? This article walks through the numbers so you can judge the stock's value with more confidence. The stock closed at US$235.66 and has returns of 1.5% over 7 days, 3.9% over 30 days, 13.7% year to date, 55.6% over 1 year, 56.6% over 3 years, and 65.6% over 5 years. This gives useful context before looking at valuation. Recent headlines around Johnson & Johnson have focused on its...

Two retirees walk into retirement with the same amount of money. One builds a portfolio that pays $120,000 a year but barely grows. The other settles for $65,000 a year and focuses on dividend growth. At first glance, the first retiree appears to have won. Twenty-five years later, the second retiree may have collected more ... The Retiree Who Chose $65,000 Instead of $120,000 and Ended Up Richer

The iShares Core Dividend Growth ETF (NYSEARCA:DGRO) was built for investors who want a paycheck that gets bigger every year, not a yield chase. DGRO tracks the Morningstar US Dividend Growth Index, screening for companies with at least five consecutive years of dividend growth and payout ratios under 75%. The fund pays a roughly 2.2% ... 64 Years of Raises: How DGRO Finds Companies That Never Cut Dividends

The investment is anticipated to enhance J&J’s supply chain resilience regarding production of its ACUVUE contact lenses.

A rank-and-file member of Congress earns $174,000 per year. A dividend portfolio can generate the same level of income without a campaign, constituents, or a weekly commute to Washington. Unlike a salary, however, this income is tied to capital, which means the size of the portfolio matters far more than the title attached to the ... This $1.7 Million Portfolio Pays More Than a Member of Congress

PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.